Views: 1461 Downloads: 162

Ameerah Abdulelah Radhi , Iman Sabah Jaafar

Abstract

The development of pharmaceutical cocrystals has recently been recognized as a fruitful approach to improving the dissolution rate and hence the bioavailability of drugs belonging to class II in the biopharmaceutical classification system (BCS). Different types of coformers, including ibuprofen, were screened for the potential synthesis of cocrystal solid forms with a non-steroidal anti-inflammatory agent, meloxicam, in an attempt to modify its dissolution rate into favorable higher values. Nine formulations were prepared using the solvent evaporation method, and the products were characterized by differential scanning calorimetry (DSC), in-vitro release studies, and powder X-ray diffraction (PXRD). Data obtained from FTIR, DSC, and PXRD spectra strongly supported the development of a new crystalline state. In addition, formulation F6, which contains meloxicam: oxalic acid dihydrate at a molar ratio of 1:2, exhibited a better dissolution pattern than pure meloxicam and other formulations, therefore, it was selected as the optimum formulation. Among the coformers explored throughout the study, oxalic acid dihydrate successfully produced cocrystals that achieved a significant enhancement in the dissolution rate compared to meloxicam‎.

Citation Formats: